When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CYAD - Celyad Oncology doses first patient in KEYNOTE-B79 Phase 1b trial
Celyad SA
Celyad Oncology (NASDAQ:CYAD) announces the first patient was dosed in the KEYNOTE-B79 Phase 1b trial. The trial will evaluate the Company’s lead developmental candidate, CYAD-101, with Merck's anti-PD-1 therapy, Keytruda (pembrolizumab), in patients with refractory metastatic colorectal cancer (mCRC) with microsatellite stable (MSS)/mismatch-repair proficient disease. Preliminary data are expected next year.